More than 10 European startups became unicorns this year

Europe's venture capital market is demonstrating sustained strength, with 12 startups achieving unicorn status in the first half of 2025, signaling a robust funding environment post-summer. Significant capital inflows are concentrated in high-growth sectors such as AI, biotech, and defense tech, exemplified by companies like Lovable, Quantum Systems, and Verdiva Bio. This consistent creation of billion-dollar companies, despite fewer mega-rounds, suggests continued investor confidence and a positive outlook for the remainder of the year.

Analysis

The European venture capital market demonstrated robust activity in the first half of 2025, generating 12 new unicorns and signaling strong investor confidence heading into the post-summer funding season. Despite a reported decline in mega-rounds from 2021 levels, significant capital deployment is evident, with several startups securing substantial funding. Notable examples include AI drug-discovery platform Isomorphic Labs raising $600 million, biotech firm Verdiva Bio securing a $410 million Series A, and preventative health startup Neko Health closing a $260 million Series B at a $1.8 billion valuation. The speed of value creation is also remarkable, as seen with AI coding startup Lovable reaching a $1.8 billion valuation just eight months after its launch. Investment themes are highly concentrated in future-focused sectors: Artificial Intelligence is a dominant thread, featured in ventures from workflow automation (Tines) to conversational platforms (Parloa). Defense and dual-use technology have also attracted significant capital, with German and Portuguese drone startups Quantum Systems and Tekever both reaching unicorn status. This trend extends to biotech, with Verdiva Bio targeting the lucrative GLP-1 market, and cybersecurity, highlighted by Zama's funding for its homomorphic encryption technology. The involvement of public companies like Alphabet, whose spin-off Isomorphic Labs validated its high potential, and Porsche SE, an investor in Quantum Systems, underscores the strategic interest of established players in this new wave of innovation.

Key Decisions for Investors

• Investors should prioritize portfolio exposure to the clear winning themes in European private markets, notably enterprise AI, dual-use/defense technology, and specialized biotech like GLP-1 therapies and AI-driven drug discovery.
• Holders of public equities like Alphabet (GOOGL), Porsche SE (POAHY), and Spotify (SPOT) should consider the successful unicorn valuations of their respective spin-offs or founder-led ventures as positive validation of their long-term innovation strategy and potential future value catalysts.
• Given the rapid and substantial late-stage funding rounds for firms like Lovable and Isomorphic Labs, crossover funds and investors with private market access should actively monitor this cohort for attractive pre-IPO investment opportunities.
• The emergence of well-funded, specialized competitors like streaming service Mubi suggests that investors in large-cap incumbents like Netflix should assess the cumulative long-term risk of market share erosion from a growing number of niche challengers.